(R)-1-benzyl-5-methyl-1,4-diazepane

Our business team has been engaged in the pharmaceutical & chemical field since 1998, with the main product lines of APIs, intermediates & fine chemicals. The sales volume in 2022 exceeded US$89 million. The company has always been focusing on the integration of trade, manufacturing & technology, market-oriented, & adhering to the strategy of professional & international development. The company has established a wide range of strategic partnerships with various upstream and downstream customers, having a number of well-known pharmaceutical & chemical companies’ authorized agency agreement of their hot products. The company has strong channel advantages in Latin America, South Asia, CIS & Africa market. Based on high technology and R&D innovation, the company has actively worked with domestic research companies, laboratories & factories to provide customers with customized R&D and production services. The company's object is to try to help customers meet their full needs in the manufacturing process by a more economical and creative way and is committed to become a trusted expert for the manufacturing process needs solution in pharmaceutical & chemical industries.